Introducing new vaccines into developing countries: obstacles, opportunities and complexities
- 5 April 2005
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 11 (S4) , S12-S15
- https://doi.org/10.1038/nm1225
Abstract
Infectious diseases are thought to account for nearly 25% of all deaths worldwide, and extract a disproportionate toll in developing countries. Moreover, infectious diseases are now appreciated to be major causes of the poverty and economic underdevelopment that characterize the world's poorest countries. Development and deployment of new vaccines to prevent infectious diseases in developing countries have therefore become high priorities in the global health agenda.Keywords
This publication has 16 references indexed in Scilit:
- Evaluating Human Papillomavirus Vaccination ProgramsEmerging Infectious Diseases, 2004
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialThe Lancet, 2004
- Breaking new ground—are changes in immunization services needed for the introduction of future HIV/AIDS vaccines and other new vaccines targeted at adolescents?Vaccine, 2004
- Shifts in global immunisation goals (1984–2004): unfinished agendas and mixed resultsSocial Science & Medicine, 2004
- The future of rotavirus vaccines: a major setback leads to new opportunitiesThe Lancet, 2004
- Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countriesVaccine, 2003
- New tendencies and strategies in international immunisation: GAVI and The Vaccine FundVaccine, 2003
- ECONOMICS OF VACCINES: FROM VACCINE CANDIDATE TO COMMERCIALIZED PRODUCTPublished by Elsevier ,2003
- Evaluating New Vaccines for Developing CountriesJAMA, 1996
- TRIAL OF AN ATTENUATED BOVINE ROTAVIRUS VACCINE (RIT 4237) IN GAMBIAN INFANTSThe Lancet, 1987